Related references
Note: Only part of the references are listed.Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04) a randomised, multicentre, open-label phase 3 trial
Patricia Pautier et al.
LANCET ONCOLOGY (2022)
The Need for Effective Adjuvant Therapy in Uterine Leiomyosarcoma: A Single-centre Experience
Emrah Eraslan et al.
JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN (2021)
Soft-tissue sarcoma in adults: An update on the current state of histiotype-specific management in an era of personalized medicine
Adriana C. Gamboa et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas The ANNOUNCE Randomized Clinical Trial
William D. Tap et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Imaging of tumour response to immunotherapy
Clarisse Dromain et al.
EUROPEAN RADIOLOGY EXPERIMENTAL (2020)
The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy
Wenxiao Jia et al.
CANCER BIOLOGY & MEDICINE (2019)
CT-response patterns and the role of CT-textural features in inoperable abdominal/retroperitoneal soft tissue sarcomas treated with trabectedin
Michael Esser et al.
EUROPEAN JOURNAL OF RADIOLOGY (2018)
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
Beatrice Seddon et al.
LANCET ONCOLOGY (2017)
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial
William D. Tap et al.
LANCET ONCOLOGY (2017)
The Influence of Primary Site on Outcomes in Leiomyosarcoma A Review of Clinicopathologic Differences Between Uterine and Extrauterine Disease
Mohamad Farid et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2013)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
High-Grade Soft-Tissue Sarcomas: Tumor Response Assessment-Pilot Study to Assess the Correlation between Radiologic and Pathologic Response by Using RECIST and Choi Criteria
Silvia Stacchiotti et al.
RADIOLOGY (2009)
Share Paper
